Cost of illness of stage IV non-small cell lung cancer (NSCLC) positive for programmed cell death ligand 1 (PD-L1) in the US

Autor: Joshua E, Kessler, Kwon N, Park, Amy J, Grizzle, Jason T, Hurwitz

Publikováno v: Expert Review of Pharmacoeconomics & Outcomes Research. 23:55-61

Non-small cell lung cancer (NSCLC) positive for programmed cell death ligand 1 (PD-L1) may be eligible for targeted immunotherapies. Literature does not currently estimate direct costs associated with this population. We aimed to identify the total d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1102bb6499ef8f85b3fd4992e443908
https://doi.org/10.1080/14737167.2023.2140141

Cost-Effectiveness of PD-L1 Testing in Non-Small Cell Lung Cancer (NSCLC) Using In Vitro Diagnostic (IVD) Versus Laboratory-Developed Test (LDT)

Autor: Jason T. Hurwitz, Shannon Vaffis, Amy J. Grizzle, Søren Nielsen, Andrew Dodson, Suzanne Parry

Publikováno v: Hurwitz, J T, Vaffis, S, Grizzle, A J, Nielsen, S, Dodson, A & Parry, S 2022, ' Cost-Effectiveness of PD-L1 Testing in Non-Small Cell Lung Cancer (NSCLC) Using In Vitro Diagnostic (IVD) Versus Laboratory-Developed Test (LDT) ', Oncology and therapy, vol. 10, no. 2, pp. 391-409 . https://doi.org/10.1007/s40487-022-00197-1

INTRODUCTION: Accurate PD-L1 testing for non-small cell lung cancer (NSCLC) maximizes the benefits of immune checkpoint inhibitor (ICI) drugs like pembrolizumab. False negative test results deny ICI treatments to eligible patients, worsening clinical

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7c9792d298b6597ff2c29888134c19d
https://pubmed.ncbi.nlm.nih.gov/35556235

Real-World Evidence from the Integrative Medicine Primary Care Trial (IMPACT): Assessing Patient-Reported Outcomes at Baseline and 12-Month Follow-Up

Autor: Ivo Abraham, Victoria Maizes, Robert L. Crocker, Jason T. Hurwitz, Andrew Weil, Randy Horwitz, Amy J. Grizzle, Rick A. Rehfeld

Publikováno v: Evidence-Based Complementary and Alternative Medicine, Vol 2019 (2019)
Evidence-based Complementary and Alternative Medicine : eCAM

Purpose. The University of Arizona Integrative Health Center (UAIHC) was an innovative membership-supported integrative medicine (IM) adult primary care clinic in Phoenix, Arizona. UAIHC delivered healthcare using an integrative medicine model that c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46d2219daf22fe7ad9d00e0c93f8945e
https://doi.org/10.1155/2019/8595409

Identifying Common Methods Used by Drug Interaction Experts for Finding Evidence About Potential Drug-Drug Interactions: Web-Based Survey

Autor: Amy J. Grizzle, John R. Horn, Daniel C. Malone, Britney A Stottlemyer, Jodi Schneider, Carol Collins, Richard D. Boyce

Publikováno v: Journal of Medical Internet Research

Background: Preventing drug interactions is an important goal to maximize patient benefit from medications. Summarizing potential drug-drug interactions (PDDIs) for clinical decision support is challenging, and there is no single repository for PDDI

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffeedcf7291f5267a9a9aff803994116
http://europepmc.org/articles/PMC6682289

Testing the face validity and inter-rater agreement of a simple approach to drug-drug interaction evidence assessment

Autor: Lisa E. Hines, Harry Hochheiser, Olga V. Kravchenko, Daniel C. Malone, Amy J. Grizzle, Richard D. Boyce

Publikováno v: J Biomed Inform

Low concordance between drug-drug interaction (DDI) knowledge bases is a well-documented concern. One potential cause of inconsistency is variability between drug experts in approach to assessing evidence about potential DDIs. In this study, we exami

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8746bbb27d4bac53ac83c01e6849be27
https://doi.org/10.1016/j.jbi.2019.103355